Dosis de Carga de Apixaban para TVP

Régimen de Dosificación para TVP Aguda

• La dosis de carga de apixaban para el tratamiento de trombosis venosa profunda (TVP) aguda es 10 mg por vía oral dos veces al día durante los primeros 7 días, seguida de 5 mg dos veces al día para completar el tratamiento, según el National Comprehensive Cancer Network 1, 2
• La fase de mantenimiento después del día 7 consiste en 5 mg por vía oral dos veces al día durante al menos 6 meses 1, 2

Evidencia de Eficacia

• El ensayo AMPLIFY demostró que el régimen de dosificación de apixaban fue no inferior a la terapia convencional para prevenir TVP recurrente o muerte relacionada con TVP, con una incidencia significativamente menor de sangrado mayor (2.3% vs 2.7%; riesgo relativo 0.84; IC 95%, 0.60-1.18), según el National Comprehensive Cancer Network 1, 2

Consideraciones Especiales

Función Renal

• Se debe evitar el uso de apixaban en pacientes con depuración de creatinina <15 mL/min, según el National Comprehensive Cancer Network 1, 2, 3, 4
• La eliminación renal representa aproximadamente 27% del aclaramiento total del fármaco 1, 2, 4

Función Hepática

• Se debe evitar el uso de apixaban en pacientes con transaminasas >2 veces el límite superior normal o bilirrubina total >1.5 veces el límite superior normal, según el National Comprehensive Cancer Network 1, 2, 3, 4

Limitaciones en Pacientes con Cáncer

• Las guías del National Comprehensive Cancer Network no recomiendan apixaban para tromboprofilaxis o tratamiento de TVP en pacientes con cáncer debido a datos clínicos insuficientes en esta población 1, 2, 3, 4

Laboratory Monitoring for Acute VTE on Apixaban

Baseline Laboratory Assessment

• The National Comprehensive Cancer Network recommends obtaining a complete blood count (CBC) to establish baseline platelet count and hemoglobin in patients on apixaban for acute VTE 5

Periodic Monitoring During Treatment

• The National Comprehensive Cancer Network suggests assessing CBC if clinical bleeding is suspected to evaluate for anemia or thrombocytopenia in patients on apixaban for acute VTE 5

What NOT to Monitor

• The American Society of Anesthesiologists notes that anti-factor Xa activity testing is not recommended for routine monitoring of apixaban's anticoagulant effect, as dosing is fixed and not adjusted based on laboratory values 6
• The Mayo Clinic and Blood advances indicate that D-dimer levels are not indicated for monitoring treatment response once VTE is confirmed and treatment initiated 7, 8

Clinical Monitoring Priorities

• The National Comprehensive Cancer Network emphasizes the importance of clinical assessment for signs of recurrent VTE, such as new leg swelling, chest pain, or dyspnea, in patients on apixaban for acute VTE 5

Special Circumstances Requiring Laboratory Assessment

• The British Medical Journal recommends obtaining a platelet count if heparin-induced thrombocytopenia is suspected or if unexplained bleeding occurs in patients on apixaban for acute VTE 9

Apixaban Monitoring and Treatment Guidelines

Introduction to Apixaban Treatment

• The American College of Chest Physicians recommends against INR monitoring for patients on direct oral anticoagulants like apixaban, as it is clinically irrelevant 10
• Apixaban is a direct factor Xa inhibitor with fixed dosing that does not require laboratory monitoring, unlike warfarin which requires INR-guided dose adjustments 10

Renal Function and Apixaban Dosing

• Renal function assessment is necessary, as apixaban should be avoided when creatinine clearance <15 mL/min 11

Evidence Supporting Apixaban Efficacy

• Apixaban was noninferior to enoxaparin/warfarin for preventing recurrent VTE or VTE-related death, with a relative risk of 0.84 (95% CI 0.60-1.18) 11
• Major bleeding was significantly lower with apixaban, with a relative risk of 0.31 (95% CI 0.17-0.55; P<0.001) 11
• Current guidelines recommend DOACs like apixaban over warfarin for acute VTE treatment in non-cancer patients, with a Strong Recommendation and Moderate-Certainty Evidence 10